Combination 5-fluorouracil, folinic acid and cisplatin (LV5FU2-CDDP) followed by gemcitabine or the reverse sequence in metastatic pancreatic cancer: Final results of a randomised strategic phase III trial (FFCD 0301)

Gut

Volumn 59, Issue 11, 2010, Pages 1527-1534

  Dahan, Laetitia ^a   Bonnetain, Frank ^b   Ychou, Marc ^c   Mitry, Emmanuel ^d,e   Gasmi, Mohamed ^f   Raoul, Jean Luc ^g   Cattan, Stéphane ^h   Phelip, Jean Marc ⁱ   Hammel, Pascal ^j   Chauffert, Bruno ^k   Michel, Pierre ^l   Legoux, Jean Louis ^m   Rougier, Philippe ^d,e   Bedenne, Laurent ^b   Seitz, Jean François ^a,n  

^a TIMONE HOSPITAL   (France)

^b Chu   (France)

^c CENTRE VAL D AURELLE   (France)

^d HÔPITAL AMBROISE PARÉ   (France)

^e LABORATOIRE DES SCIENCES DU CLIMAT ET DE L ENVIRONNEMENT   (France)

^f HÔPITAL NORD   (France)

^g CENTRE EUGÈNE MARQUIS   (France)

^h LILLE UNIVERSITY HOSPITAL   (France)

ⁱ GRENOBLE UNIVERSITY HOSPITAL   (France)

^j BEAUJON HOSPITAL   (France)

^k Georges Francois Leclerc Anticancer Centre   (France)

^l ROUEN UNIVERSITY HOSPITAL   (France)

^m Centre Hospitalier Régional   (France)

ⁿ ASSISTANCE PUBLIQUE HÔPITAUX DE MARSEILLE   (France)

more..

Author keywords

[No Author keywords available]

Indexed keywords

CISPLATIN; FLUOROURACIL; FOLINIC ACID; GEMCITABINE; ANTINEOPLASTIC AGENT; DEOXYCYTIDINE; DRUG DERIVATIVE;

ADULT; AGED; ARTICLE; BLOOD TOXICITY; BONE MARROW DEPRESSION; CANCER COMBINATION CHEMOTHERAPY; CANCER GROWTH; CANCER PATIENT; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; FEMALE; FOLLOW UP; HUMAN; MAJOR CLINICAL STUDY; MALE; METASTASIS; MULTICENTER STUDY; MULTIPLE CYCLE TREATMENT; NAUSEA; OVERALL SURVIVAL; PANCREAS ADENOCARCINOMA; PHASE 3 CLINICAL TRIAL; PRIORITY JOURNAL; PROGRESSION FREE SURVIVAL; RANDOMIZED CONTROLLED TRIAL; TREATMENT RESPONSE; VOMITING; ADENOCARCINOMA; DISEASE COURSE; DRUG ADMINISTRATION; FRANCE; MIDDLE AGED; PANCREAS TUMOR; PATHOLOGY; SURVIVAL; TREATMENT OUTCOME;

ADENOCARCINOMA; ADULT; AGED; AGED, 80 AND OVER; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CISPLATIN; DEOXYCYTIDINE; DISEASE PROGRESSION; DRUG ADMINISTRATION SCHEDULE; FEMALE; FLUOROURACIL; FRANCE; HUMANS; LEUCOVORIN; MALE; MIDDLE AGED; PANCREATIC NEOPLASMS; SURVIVAL ANALYSIS; TREATMENT OUTCOME;

EID: 78049497383     PISSN: 00175749     EISSN: 14683288     Source Type: Journal    
DOI: 10.1136/gut.2010.216135     Document Type: Article

References (33)

1. Gudjonsson B. Cancer of the pancreas. 50 years of surgery. Cancer 1987;60:2284-303.
2. Burris HA 3rd, Moore MJ, Andersen J, et al. Improvements in survival and clinical benefit with gemcitabine as first-line therapy for patients with advanced pancreas cancer: a randomized trial. J Clin Oncol 1997;15:2403-13.
3. Louvet C, Labianca R, Hammel P, et al. Gemcitabine in combination with oxaliplatin compared with gemcitabine alone in locally advanced or metastatic pancreatic cancer: results of a GERCOR and GISCAD phase III trial. J Clin Oncol 2005;23:3509-16.
4. Abou Alfa GK, Letourneau R, Harker WG, et al. Randomized phase III study of exatecan and gemcitabine compared with gemcitabine alone in untreated advanced pancreatic cancer. J Clin Oncol 2006;24:4441-7.
5. Rocha Lima CM, Green MR, Rotche R, et al. Irinotecan plus gemcitabine results in no survival advantage compared with gemcitabine monotherapy in patients with locally advanced or metastatic pancreatic cancer despite increased tumor response rate. J Clin Oncol 2004;22:3776-83.
6. Heinemann V, Quietzsch D, Gieseler F, et al. Randomized phase III trial of gemcitabine plus cisplatin compared with gemcitabine alone in advanced pancreatic cancer. J Clin Oncol 2006;24:3946-52.
7. Oettle H, Richards DA, Ramanathan RK, et al. A phase III trial of pemetrexed plus gemcitabine versus gemcitabine in patients with unresectable or metastatic pancreatic cancer. Ann Oncol 2005;16:1639-45.
8. Philip PA, Benedetti J, Fenoglio-Preiser C, et al. Phase III study of gemcitabine plus cetuximab versus gemcitabine in patients with locally advanced or metastatic pancreatic adenocarcinoma: SWOG S0205 study. Proc Am Soc Clin Oncol 2007;25:4509.
9. Kindler HL, Niedzwiecki D, Hollis D, et al. A double-blind, placebo-controlled, randomized phase III trial of gemcitabine plus bevacizumab versus gemcitabine plus placebo in patients with advanced pancreatic cancer: a preliminary analysis of cancer and leukemia group B (CALGB). Proc Am Soc Clin Oncol 2007;25:4508.
10. Moore MJ, Goldstein D, Hamm J, et al. Erlotinib plus gemcitabine compared with gemcitabine alone in patients with advanced pancreatic cancer: a phase III trial of the National Cancer Institute of Canada Clinical Trials Group. J Clin Oncol 2007;25:1960-6.
11. Rougier P, Zarba JJ, Ducreux M, et al. Phase II study of cisplatin and 120-hour continuous infusion of 5-fluorouracil in patients with advanced pancreatic adenocarcinoma. Ann Oncol 1993;4:333-6.
12. Ducreux M, Rougier P, Pignon JP, et al. A randomised trial comparing 5-FU with 5-FU plus cisplatin in advanced pancreatic carcinoma. Ann Oncol 2002;13:1185-91.
13. Taieb J, Lecomte T, Ezenfis J, et al. 5-FU, folinic acid and cisplatin (LV5FU2-P) for unresectable pancreatic cancer. Gastroenterol Clin Biol 2002;26:605-9.
14. Colucci G, Labianca R, Di Costanzo F, et al. Gruppo Oncologico Italia Meridionale (GOIM); Gruppo Italiano per lo Studio dei Carcinomi dell'Apparato Digerente (GISCAD); Gruppo Oncologico Italiano di Ricerca Clinica (GOIRC). Randomized phase III trial of gemcitabine plus cisplatin compared with single-agent gemcitabine as firstline treatment of patients with advanced pancreatic cancer: the GIP-1 study. J Clin Oncol 2010;28:1645-51.
15. Rothenberg ML, Moore MJ, Cripps MC, et al. A phase II trial of gemcitabine in patients with 5-FU-refractory pancreas cancer. Ann Oncol 1996;7:347-53.
16. Mitry E, Ducreux M, Ould-Kaci M, et al. Oxaliplatin combined with 5-FU in second line treatment of advanced pancreatic adenocarcinoma. Results of a phase II trial. Gastroenterol Clin Biol 2006;30:357-63.
17. Oettle H, Arnold D, Esser M, et al. Paclitaxel as weekly second-line therapy in patients with advanced pancreatic carcinoma. Anticancer Drugs 2000;11:635-8.
18. Kozuch P, Grossbard ML, Barzdins A, et al. Irinotecan combined with gemcitabine, 5-fluorouracil, leucovorin, and cisplatin (G-FLIP) is an effective and noncrossresistant treatment for chemotherapy refractory metastatic pancreatic cancer. Oncologist 2001;6:488-95.
19. Ulrich-Pur H, Raderer M, Verena Kornek G, et al. Irinotecan plus raltitrexed vs raltitrexed alone in patients with gemcitabine-pretreated advanced pancreatic adenocarcinoma. Br J Cancer 2003;88:1180-4.
20. Cantore M, Rabbi C, Fiorentini G, et al. Combined irinotecan and oxaliplatin in patients with advanced pre-treated pancreatic cancer. Oncology 2004;67:93-7.
21. Milella M, Gelibter A, Di Cosimo S, et al. Pilot study of celecoxib and infusional 5-fluorouracil as second-line treatment for advanced pancreatic carcinoma. Cancer 2004;101:133-8.
22. Tsavaris N, Kosmas C, Skopelitis H, et al. Second-line treatment with oxaliplatin, leucovorin and 5-fluorouracil in gemcitabine-pretreated advanced pancreatic cancer: a phase II study. Invest New Drugs 2005;23:369-75.
23. Reni M, Pasetto L, Aprile G, et al. Raltitrexedeeloxatin salvage chemotherapy in gemcitabine-resistant metastatic pancreatic cancer. Br J Cancer 2006;94:785-91.
24. Reni M, Cereda S, Mazza E, et al. PEFG (cisplatin, epirubicin, 5-fluorouracil, gemcitabine) regimen as second-line therapy in patients with progressive or recurrent pancreatic cancer after gemcitabine-containing chemotherapy. Am J Clin Oncol 2008;31:145-50.
25. Demols A, Peeters M, Polus M, et al. Gemcitabine and oxaliplatin (GEMOX) in gemcitabine refractory advanced pancreatic adenocarcinoma: a phase II study. Br J Cancer 2006;94:481-5.
26. Ignatiadis M, Polyzos A, Stathopoulos GP, et al. A multicenter phase II study of docetaxel in combination with gefitinib in gemcitabine-pretreated patients with advanced/metastatic pancreatic cancer. Oncology 2006;71:159-63.
27. Gebbia V, Maiello E, Giuliani F, et al. Second-line chemotherapy in advanced pancreatic carcinoma: a multicenter survey of the Gruppo Oncologico Italia Meridionale on the activity and safety of the FOLFOX4 regimen in clinical practice. Ann Oncol 2007;18:vi124-7.
28. Togawa A, Yoshitomi H, Ito H, et al. Treatment with an oral fluoropyrimidine, S-1, plus cisplatin in patients who failed postoperative gemcitabine treatment for pancreatic cancer: a pilot study. Int J Clin Oncol 2007;12:268-73.
29. Wolpin BM, Hezel AF, Abrams T, et al. Oral mTOR inhibitor everolimus in patients with gemcitabine-refractory metastatic pancreatic cancer. J Clin Oncol 2009;27:193-8.
30. Ko AH, Dito E, Schillinger B, et al. A phase II study evaluating bevacizumab in combination with fixed-dose rate gemcitabine and low-dose cisplatin for metastatic pancreatic cancer: is an anti-VEGF strategy still applicable? Invest New Drugs 2008;26:463-71.
31. Boeck S, Weigang-Köhler K, Fuchs M, et al. Second-line chemotherapy with pemetrexed after gemcitabine failure in patients with advanced pancreatic cancer: a multicenter phase II trial. Ann Oncol 2007;18:745-51.
32. Oettle H, Pelzer U, Stieler J, et al. Oxaliplatin/folinic acid/5-fluorouracil (OFF) in second line therapy of gemcitabine-refractory advanced pancreatic cancer (CONKO 003). Proc Am Soc Clin Oncol 2005;23:4031.
33. Pelzer U, Kubica K, Stieler J, et al. A randomized trial in patients with gemcitabine refractory pancreatic cancer. Final results of the CONKO 003 study. Proc Am Soc Clin Oncol 2008;26:4508.